Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04839562 · ClinicalTrials.gov registry record · Phase 2
A Controlled Study of Solriamfetol for Attention Deficit Hyperactivity Disorder (ADHD) in Adults
A Phase 2 study, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- Phase 2
- Development phase
- 66
- Enrollment target
NCT04839562: Completed Phase 2 study, sponsored by Massachusetts General Hospital.
NCT04839562 is a Phase 2 study that has completed, run by Massachusetts General Hospital. The registered enrollment target is 66 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04839562, a Phase 2 study, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 66 participants
- Enrollment target
Study Summary
A double-blind, placebo controlled study of solriamfetol for adults age 18 to 65 with diagnosis of Attention Deficit Hyperactivity Disorder.
Interventions
- OTHER Placebo
- DRUG Solriamfetol 150 MG
- DRUG Solriamfetol 75 MG
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 66 participants |
| Start Date | 2021-08-06 |
| Est. Completion | 2023-01-27 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04839562
The ClinicalTrials.gov registry entry for NCT04839562 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 66 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT04839562 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04839562 about?
NCT04839562 is a clinical study titled "A Controlled Study of Solriamfetol for Attention Deficit Hyperactivity Disorder (ADHD) in Adults". A double-blind, placebo controlled study of solriamfetol for adults age 18 to 65 with diagnosis of Attention Deficit Hyperactivity Disorder.
What is the current status of trial NCT04839562?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 66 participants. The study started on 2021-08-06. Estimated completion is 2023-01-27.
What interventions are being tested in trial NCT04839562?
The interventions under investigation include: Placebo (OTHER), Solriamfetol 150 MG (DRUG), Solriamfetol 75 MG (DRUG).
Who is sponsoring clinical trial NCT04839562?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.